3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
18
Carcinoma, Hepatocellular
9
Neoplasms
8
Melanoma
7
Squamous Cell Carcinoma of Head and Neck
6
Nasopharyngeal Carcinoma
6
Triple Negative Breast Neoplasms
5
Neoplasm Metastasis
5
Esophageal Neoplasms
5
Recurrence
4
Esophageal Squamous Cell Carcinoma
4
Colonic Neoplasms
4
Stomach Neoplasms
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Solid Cancers
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Gastric / Gastroesophageal Junction Adenocarcinoma
2
EBV-associated Tumors
2
Cholangiocarcinoma
2
Breast Neoplasms
2
Bites and Stings
2
Biliary Tract Neoplasms
2
Advanced Solid Tumors
2
Interventions
Nivolumab
3
Oxaliplatin
2
Capecitabine
2
trifluridine tipiracil drug combination
1
sintilimab
1
relatlimab
1
regorafenib
1
dabrafenib
1
copanlisib
1
atezolizumab
1
Tiragolumab
1
Leucovorin
1
Immune Checkpoint Inhibitors
1
Fulvestrant
1
Fluorouracil
1
Cetuximab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Spinocerebellar Degenerations
×
Immune Checkpoint Inhibitors
×
1 year
×
Clear all
NCT07551479
2026-04-24
TORCH-STAR
Fudan University
Phase 3
Not yet recruiting
612 enrolled